• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 20, 2015

View Archived Issues

Pharma: Other news to note

strong>Abbvie Inc., of North Chicago, said it entered an exclusive worldwide license agreement with C2N Diagnostics, of St. Louis, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's disease and other neurological disorders. Read More

In the clinic

Creabilis Ltd., of Canterbury, UK, published positive phase IIb data for its TrkA kinase inhibitor, CT327, in Acta Dermato-Venereologica. Read More

Other news to note

Bioinvent International AB, of Lund, Sweden, completed a strategic analysis of its ICAM-1-targeted phase II antibody, BI-505, to seek input from thought leaders with respect to the development program. Read More

Financings

Galena Biopharma Inc., of Portland, Ore., closed a public offering of about 24.4 million shares of common stock and warrants to purchase an aggregate of nearly 12.2 million shares of common stock at an exercise price of $2.08 per share. Read More

Stock movers

Read More

Regulatory front

The Biotechnology Industry Organization (BIO) released an independent study documenting the impact of academia-industry technology transfer to the U.S. economy. Titled "The Economic Contribution of University/Nonprofit Inventions in the United States: 1996-2013," the report tracks academia-industry patent licensing over that 18-year period, estimating that it bolstered U.S. gross industry output by up to $1.18 trillion, U.S. gross domestic product by up to $518 billion and supported about 3.8 million U.S. jobs. Read More

Pre-op ANP boosts lung cancer surgery survival

HONG KONG – Preoperative atrial natriuretic peptide (ANP) improved survival in lung cancer patients undergoing surgery and appeared to prevent cancer metastasis through prevention of vascular endothelial inflammation and adhesion in mice, Japanese researchers reported in the March 16, 2015, early edition of the Proceedings of the National Academy of Sciences. Read More

Keeping corruption at bay: Pharma's ongoing challenge in China

SHANGHAI – In the almost two years since Chinese police said they were investigating Glaxosmithkline plc for corruption, the industry here has seen compliance go from a mid-level priority, second to meeting ambitious sales targets, to a board-level issue directly concerning senior management teams and those legally responsible for the business. Read More

Sanofi R&D chief cites regulatory, scientific needs in keynote

LONDON – It was a love-in to celebrate the 20th anniversary of the EMA and the start of centralized approvals across Europe, but Elias Zerhouni, president of global R&D at Sanofi SA, pulled few punches in his keynote address, calling for greater consistency, increased speed and a more science-based approach to regulation. Read More

Lyxumia hits the mark in cardiovascular safety study

DUBLIN – Lyxumia (lixisenatide), the glucagon-like peptide 1 (GLP-1) agonist, which Zealand Pharma A/S out-licensed to Sanofi SA, is on track for a third-quarter new drug application (NDA) filing, following a cardiovascular safety study in which the drug had a similar profile to placebo. Read More

Assembly Biosciences raising $75M to battle HBV and CDAD

Less than a year after joining Nasdaq through a merger, Assembly Biosciences Inc. is tapping keen interest in the science behind its potentially curative preclinical hepatitis B virus (HBV) and Clostridium difficile-associated diarrhea (CDAD) programs through a $75 million public offering that will carry it well into 2017 or beyond. Read More

CAR T mystique lassos City of Hope: Coronado to advance technology at Mustang

If anyone still doubted the power of chimeric antigen receptor T-cell (CAR T) technology to propel pipelines and stock prices, they needed look no further than the cross-country deal between Coronado Biosciences Inc. and the City of Hope to advance a portfolio of assets in newly created Mustang Therapeutics Inc. Read More

Pharma: In the clinic

Pfizer Inc., of New York, said the findings from its Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) have been published in the March 19, 2015, issue of The New England Journal of Medicine. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • Handshake with DNA, molecules

    Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

    BioWorld
    Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • 3D illustration of pancreatic cancer

    ASCO 2025: Verastem has positive cancer data but stock sags

    BioWorld
    New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe